Genmab's blood cancer drug fails main goal in late-stage study
Jan 16 (Reuters) - Danish drugmaker Genmab GMAB.CO said on Friday that its experimental drug for a type of blood cancer failed to meet the main goal in a late-stage study. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Alan Barona) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on Genmab A/S
See all newsBrief: Genmab Says Orbis Investment Management Holds 4.99% Of Genmab Voting Rights As Of June 12
Brief: Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Brief: Genmab Presents Epcore Fl-1 Data Showing Consistent Efficacy, Safety For Epcoritamab Combination
Brief: Genmab Says Orbis Investment Management Limited Holds 5.08% Of Genmab A/S As Of May 8, 2026
Genmab falls after 'uneventful' Q1, profit miss